Compare WASH & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WASH | AKBA |
|---|---|---|
| Founded | 1800 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 682.2M | 729.1M |
| IPO Year | 1994 | 2014 |
| Metric | WASH | AKBA |
|---|---|---|
| Price | $34.39 | $1.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $31.25 | $5.75 |
| AVG Volume (30 Days) | 104.3K | ★ 3.3M |
| Earning Date | 04-29-2026 | 05-27-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 266.26 | 93.94 |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $229,048,000.00 | N/A |
| Revenue This Year | N/A | $1.84 |
| Revenue Next Year | $6.19 | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | ★ 127.57 | N/A |
| 52 Week Low | $24.97 | $1.14 |
| 52 Week High | $37.08 | $4.08 |
| Indicator | WASH | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 43.18 |
| Support Level | $26.60 | $1.14 |
| Resistance Level | $37.08 | $1.57 |
| Average True Range (ATR) | 1.24 | 0.10 |
| MACD | -0.34 | 0.01 |
| Stochastic Oscillator | 51.66 | 22.83 |
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, and wealth management and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.